Past Meeting| Keystone Symposia

Web Desc
Cancer and Metabolism joint with Advances in Hypoxic Signaling: From Bench to Bedside Organizer(s): Reuben J. Shaw and David M. Sabatini Date: February 12 - 17, 2012 Location: Fairmont Banff Springs, Banff, AB, Canada Sponsored by Astellas Pharma Inc., Celgene Corporation, Pfizer Inc. and Takeda Pharmaceutical Company Limited Summary of Meeting: Although altered glucose metabolism was first noted as a characteristic of tumor cells by Otto Warburg in the 1920s, the molecular underpinning for this observation did not begin to be appreciated fully until the past decade. This area has exploded over the last five years with the identification of extensive interactions of genuine tumor suppressor genes and oncogenes with metabolic control. The increased biosynthetic needs of tumor cells demand a reprogramming of cellular metabolism, which also creates increased energy demands and makes tumor cells more vulnerable to interventions targeting their metabolism. The goal of the Keystone Symposia meeting on Cancer and Metabolism is to bring together leaders in the fields of cancer and metabolic control with those studying the signaling pathways linking and governing each. The latest discoveries will be discussed as well as how this knowledge can be exploited to design future cancer therapeutics. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Advances in Hypoxic Signaling: From Bench to Bedside, which will share a keynote address and a plenary session with this meeting. Scholarship Deadline: October 13 2011 Discounted Abstract Deadline: October 13 2011 Abstract Deadline: November 14 2011 Discounted Registration Deadline: December 12 2011 Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: EMBO Young Investigator Programme We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: We gratefully acknowledge the generous grant for this conference provided by: National Cancer Institute (NCI) Grant No. 1R13CA162886-01 The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Cancer and Metabolism

joint with Advances in Hypoxic Signaling: From Bench to Bedside

Organizer(s): Reuben J. Shaw and David M. Sabatini

Date: February 12 - 17, 2012
Location: Fairmont Banff Springs, Banff, AB, Canada

Sponsored by Astellas Pharma Inc., Celgene Corporation, Pfizer Inc. and Takeda Pharmaceutical Company Limited

Summary of Meeting:

Although altered glucose metabolism was first noted as a characteristic of tumor cells by Otto Warburg in the 1920s, the molecular underpinning for this observation did not begin to be appreciated fully until the past decade. This area has exploded over the last five years with the identification of extensive interactions of genuine tumor suppressor genes and oncogenes with metabolic control. The increased biosynthetic needs of tumor cells demand a reprogramming of cellular metabolism, which also creates increased energy demands and makes tumor cells more vulnerable to interventions targeting their metabolism. The goal of the Keystone Symposia meeting on Cancer and Metabolism is to bring together leaders in the fields of cancer and metabolic control with those studying the signaling pathways linking and governing each. The latest discoveries will be discussed as well as how this knowledge can be exploited to design future cancer therapeutics. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Advances in Hypoxic Signaling: From Bench to Bedside, which will share a keynote address and a plenary session with this meeting.

Scholarship Deadline: October 13 2011

Discounted Abstract Deadline: October 13 2011

Abstract Deadline: November 14 2011

Discounted Registration Deadline: December 12 2011

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

EMBO Young Investigator Programme

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA162886-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found